Stockscreener 앱 받기
4.735
1.56%
-0.075
시간 외 거래:
4.79
0.055
+1.16%
Kodiak Sciences Inc 주식(KOD)의 최신 뉴스
Diabetic Macular Edema Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | Oxurion, Ocuphire Pharma, YD Life Science, Unity Biotechnology, Novartis - The Globe and Mail
Retinal Vein Occlusion Market Trends: Surge in Anti-VEGF - openPR.com
What makes Exagen Inc. stock price move sharplyFree Expert Investment Advice - Newser
AIW(stability world ai) Latest NewsMoney Making Low Risk Plans - Newser
What makes Kodiak Sciences Inc. stock price move sharplySteady Profit Stock Forecasts - Newser
Why ATA Creativity Global Depositary Receipt stock attracts strong analyst attentionHigh Return Intraday Picks - Newser
Why IMTX stock attracts strong analyst attentionFree Stock Market Insider Analysis - Newser
Why Kodiak Sciences Inc. stock attracts strong analyst attentionMarket Beating Strategy - Newser
Why Vine Hill Capital Investment Corp. Equity Warrant stock attracts strong analyst attentionFast Moving Stock Alerts - Newser
How Kodiak Sciences Inc. stock performs during market volatilityFree Predictions - Newser
Why Premium Income Corporation Preferred Security stock attracts strong analyst attentionExpert Backed Predictions - Newser
Why SBXD stock attracts strong analyst attentionFree Consultation - Newser
When FVRR stock expected to show significant growthIs OVLY stock a good long term investment optionFree Stock Selection - Newser
Why The Allstate Corporation Preferred Security stock attracts strong analyst attentionSmart Return Focused Trading - Newser
Penny Stocks To Watch In July 2025 - simplywall.st
Kodiak Sciences' R&D Day: A Pivotal Moment for Retinal Disease Innovation and Investor Returns - AInvest
Kodiak Sciences Reveals Pipeline Progress: 3 Phase 3 Programs Taking Center Stage at R&D Day - Stock Titan
Vontobel Holding Ltd. Purchases Shares of 10,000 Kodiak Sciences Inc. (NASDAQ:KOD) - Defense World
Diabetic Retinopathy Pipeline 2025: MOA and ROA Insights, - openPR.com
Diabetic Retinopathy Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | | Kodiak Sciences, Novartis, Regenxbio Inc., OcuTerra Therapeutics - Barchart.com
Kodiak Sciences to present KSI-101 highlights at the 2025 Congress of the International Ocular Inflammation Society (IOIS) - Ophthalmology Times
Breakthrough: Kodiak Sciences Reveals Novel Bispecific Drug Fighting Both IL-6 and VEGF in Macular Edema - Stock Titan
Wet AMD Market Size in the 7MM was ~USD 7,783 million in 2023 and is expected to increase by 2034, estimates DelveInsight - Barchart.com
New one-year results for Kodiak's tarcocimab tedromer in the pivotal BEACON trial reinforce durability signal and demonstrate matched efficacy and comparable safety and tolerability in retinal vein occlusion - The Globe and Mail
VEGF Inhibitors Therapeutic for Diabetic Retinopathy Market Analysis 2025-2034 - InsightAce Analytic
Why Is Kodiak Sciences (KOD) Up 10.5% Since Last Earnings Report? - Yahoo Finance
Millennium Management LLC Cuts Holdings in TriSalus Life Sciences, Inc. (NASDAQ:TLSI) - Defense World
Kodiak Sciences Q2 EPS Forecast Decreased by Zacks Research - Defense World
Kodiak Sciences Inc. (NASDAQ:KOD) Position Increased by Public Employees Retirement System of Ohio - Defense World
Talkspace And 2 Other Compelling Penny Stocks To Consider - simplywall.st
Retinal Vein Occlusion Pipeline Appears Robust With 15+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail
Kodiak Sciences Holds 2025 Annual Stockholders Meeting - TipRanks
Kodiak Sciences to Present at 2025 Jefferies Global Healthcare C - GuruFocus
Kodiak Sciences Reveals Latest Retinal Disease Breakthroughs at Major Healthcare Conference - Stock Titan
Kodiak Sciences to Present at 2025 Jefferies Global Healthcare Conference - Yahoo Finance
Kodiak Sciences’ SWOT analysis: eye disease biotech stock at crossroads - Investing.com Australia
Kodiak Sciences’ SWOT analysis: eye disease biotech stock at crossroads By Investing.com - Investing.com India
Kodiak Q1 Loss Wider Than Expected, Pipeline Development in Focus - The Globe and Mail
Kodal Minerals Nears Export Permit For Mali Lithium Project - Finimize
Kodiak Sciences Inc Reports Q1 2025 Earnings: EPS of -$1.09 Misses Estimates, No Revenue Reported - GuruFocus
KOD Plans to Unveil Key Developments as Phase 3 Trials Progress - GuruFocus
KOD Plans to Unveil Key Developments as Phase 3 Trials Progress | KOD Stock News - GuruFocus
Kodiak Sciences Announces Recent Business Highlights and First Q - GuruFocus
Kodiak Sciences Reports Deeper Q1 Loss: What 3 Key Phase 3 Trials Mean for Future Growth - Stock Titan
Kodiak Sciences (KOD) Projected to Post Earnings on Wednesday - Defense World
Kodiak Sciences Inc. (NASDAQ:KOD) Shares Acquired by Dimensional Fund Advisors LP - Defense World
MetLife Investment Management LLC Makes New $209,000 Investment in Kodiak Sciences Inc. (NASDAQ:KOD) - The AM Reporter
MetLife Investment Management LLC Invests $209,000 in Kodiak Sciences Inc. (NASDAQ:KOD) - Defense World
Wells Fargo & Company MN Sells 2,710 Shares of Kodiak Sciences Inc. (NASDAQ:KOD) - Defense World
Ratio Review: Analyzing Kodiak Sciences Inc (KOD)’s Price-to-Cash and Price-to-Free Cash Flow - DWinneX
Retinal vein occlusion Market: Epidemiology, Therapies, - openPR.com
BlackRock, Inc. Reduces Stake in Kodiak Sciences Inc. - GuruFocus
Kodiak Sciences Data at ARVO 2025 Highlight Power and Versatilit - GuruFocus
3.40%
2.49%
자본화:
|
볼륨(24시간):